New imaging for immunotherapy in advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a special imaging scan called [18F]-FARAG to see how well it shows the activity of immunotherapy in advanced NSCLC. The goal is to help doctors understand if the treatment is working earlier than standard scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic non-small cell lung cancer (NSCLC).
- You are planning to start or are already receiving immunotherapy (a PD-1 or PD-L1 checkpoint inhibitor) alone or with other treatments.
- Your cancer can be measured on scans (has at least one tumor that can be tracked).
- You are able to do your daily activities with little to no help (ECOG score 0–2).
- You are willing to have follow-up visits at the University of Iowa.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new PET imaging agent to see how consistently it shows immune activity in the body. It is for people with advanced non-small cell lung cancer who are about to start immunotherapy.
This study uses special PET scans to see how well your immune cells respond to immunotherapy given before surgery for non-small cell lung cancer. The goal is to learn which patients benefit most from this treatment approach.
This study uses special PET imaging to measure changes in a marker ([18F]F-AraG) in non-small cell lung cancer after starting anti–PD-1 treatment. It aims to learn whether these scan changes reflect how the cancer responds.
This study uses a special type of PET scan to look at specific cells in non-small cell lung cancer tumors that might help doctors understand how well immunotherapy treatments are working. If you are about to start immunotherapy for advanced lung cancer, you may be able to join.
This trial tests a new radioactive imaging agent that helps doctors see EGFR-positive lung cancer cells. It is for people with advanced non-small cell lung cancer that has an EGFR mutation, and who are not currently on a changing cancer treatment.
This trial tests a special PET scan (68Ga-grazytracer) to see if it can predict early whether immunotherapy is working in people with lung cancer that can be surgically removed. If successful, this scan could help doctors tailor treatment sooner.
Hear when a new Advanced Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.